ENBI Stock Overview
Operates as a biotechnology research and development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Entheon Biomedical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.31 |
| 52 Week High | CA$0.45 |
| 52 Week Low | CA$0.075 |
| Beta | 1.31 |
| 1 Month Change | 0% |
| 3 Month Change | 138.46% |
| 1 Year Change | 210.00% |
| 3 Year Change | -83.68% |
| 5 Year Change | n/a |
| Change since IPO | -94.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENBI | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -7.5% | -2.7% | -1.0% |
| 1Y | 210.0% | 2.3% | 14.4% |
Return vs Industry: ENBI exceeded the Canadian Biotechs industry which returned 2.3% over the past year.
Return vs Market: ENBI exceeded the Canadian Market which returned 14.4% over the past year.
Price Volatility
| ENBI volatility | |
|---|---|
| ENBI Average Weekly Movement | 33.2% |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: ENBI's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: ENBI's weekly volatility has decreased from 76% to 33% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1 | Timothy Ko | www.entheonbiomedical.com |
Entheon Biomedical Corp. operates as a biotechnology research and development company. It engages in developing of products for treating addiction and substance use disorders. The company is headquartered in Vancouver, Canada.
Entheon Biomedical Corp. Fundamentals Summary
| ENBI fundamental statistics | |
|---|---|
| Market cap | CA$4.30m |
| Earnings (TTM) | -CA$307.69k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.0x
P/E RatioIs ENBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENBI income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$307.69k |
| Earnings | -CA$307.69k |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ENBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 07:25 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2023/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Entheon Biomedical Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.